GDAP2 Inhibitors
GDAP2 Inhibitors are a collection of chemical compounds that exert their inhibitory effects on GDAP2 through various mechanisms by influencing signaling pathways GDAP2 is involved with. GW 5074, PD 98059, and U0126 are examples that target the MAPK/ERK pathway at different points: GW 5074 by inhibiting Raf kinase, PD 98059 by selectively inhibiting MEK, and U0126 by inhibiting MEK1/2, all leading to a decrease in GDAP2's functional activity within this pathway. Similarly, LY 294002 and Wortmannin, both PI3K inhibitors, impede the PI3K/AKT pathway, resulting in indirect suppression of GDAP2's activity. Rapamycin, an mTOR inhibitor, can also reduce GDAP2 activity by attenuating mTOR signaling, which regulates various proteins related to cellular growth where GDAP2 might play a role.
Further indirect inhibition of GDAP2 is achieved through the use of SP600125 and SB 203580, which target the stress-activated MAPK pathway by inhibiting JNK and p38 MAPK, respectively. PP 2, as a Src family kinase inhibitor, and Dasatinib, as a broad-spectrum tyrosine kinase inhibitor, diminish the functional activity of GDAP2 by interfering with signaling routesthat may involve this protein. Sorafenib, a RAF inhibitor, and PD 0332991, a CDK4/6 inhibitor, both contribute to the diminished activity of GDAP2 by blocking critical elements of the MAPK/ERK pathway and cell cycle progression, respectively. These inhibitory actions across the board serve to dampen the functional activity of GDAP2 by disrupting the signaling networks it is associated with and relies upon for its role in cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW 5074 is a potent inhibitor of the Raf kinase, which is upstream of the MAPK/ERK signaling pathway. GDAP2 is involved in this pathway, and its activity can be indirectly inhibited when GW 5074 disrupts the pathway by preventing Raf activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 selectively inhibits MEK, which is part of the MAPK/ERK pathway. By blocking MEK, PD 98059 indirectly inhibits the downstream signaling that would typically involve GDAP2, thus diminishing its functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is an inhibitor of PI3K, a key player in the AKT signaling pathway. By hindering PI3K activity, LY 294002 indirectly decreases GDAP2 activity that is modulated through this signaling cascade. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, and since mTOR signaling can regulate various proteins involved in cellular growth and survival, GDAP2 activity can be indirectly inhibited through the attenuation of this pathway by rapamycin. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, a kinase involved in the stress-activated MAPK pathway. GDAP2, being part of the cellular response mechanisms, can have its activity indirectly reduced by SP600125 as it diminishes JNK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor, which can indirectly inhibit GDAP2 by blocking the p38 MAPK pathway, a route that GDAP2 may influence in cellular stress response. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, enzymes involved in the MAPK/ERK pathway. GDAP2 activity related to this pathway can be indirectly diminished when U0126 is employed to inhibit MEK1/2. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. By blocking PI3K, it indirectly leads to the inhibition of GDAP2 activity that might be regulated through the PI3K/AKT pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP 2 is a Src family kinase inhibitor. Src kinases participate in various signaling pathways, including those that may regulate GDAP2 function. Thus, PP 2 can indirectly lead to the diminished activity of GDAP2 by inhibiting Src family kinases. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor, which can target pathways involving GDAP2. By inhibiting tyrosine kinases, Dasatinib indirectly diminishes GDAP2's functional activity. | ||||||